论文部分内容阅读
目的通过FUDR代替5-Fu用于可手术乳腺癌的术前CEF新辅助化疗中,比较两种药物的疗效和副作用。方法 90例Ⅱ期和Ⅲ期乳腺癌患者分为两组,实验组采用含FUDR的CEF方案术前新辅助化疗,对照组采用含5-Fu的CEF方案术前新辅助化疗.结果实验组CR 2例、PR 25例,RR为60.0%。对照组CR 3例、PR 22例,RR为55.6%。实验组总有效率与对照组无明显差异(P>0.05)。实验组恶心呕吐、骨髓抑制发生率均低于对照组(P<0.05),而脱发和便秘的发生率两组无明显差异(P>0.05)。结论 FUDR代替5-Fu用于乳腺癌的CEF新辅助化疗方案是一个很好的选择。
Objective To compare the efficacy and side effects of two drugs by using FUDR instead of 5-Fu in preoperative CEF neoadjuvant chemotherapy for operable breast cancer. Methods Ninety patients with stage Ⅱ and stage Ⅲ breast cancer were divided into two groups.The experimental group received preoperative neoadjuvant chemotherapy with CUD regimen containing FUDR and the control group received preoperative neoadjuvant chemotherapy with CEF regimen containing 5-Fu.Results The CR 2 cases, PR 25 cases, RR 60.0%. Control group CR 3 cases, PR 22 cases, RR was 55.6%. The total effective rate of the experimental group and the control group no significant difference (P> 0.05). The incidence of nausea and vomiting and myelosuppression in the experimental group were lower than those in the control group (P <0.05), while the incidence of hair loss and constipation had no significant difference between the two groups (P> 0.05). Conclusions FUDR is a good alternative to CEF neoadjuvant chemotherapy for breast cancer in place of 5-Fu.